Table 2.
Comparison between the median of participants with detectable biomarkers between non-small cell lung cancer (NSCLC) and healthy controls (HCs)
| Marker | NSCLC Median (IQR) | HC Median (IQR) | P-value |
|---|---|---|---|
| TGF-β (ng/dl) | 51 (40-63) | 29 (24-37) | < 0.0001 |
| SMAD2 (ng/dl) | 2.3 (1.8-2.5) | 1.5 (0.6-1.8) | < 0.0001 |
| Wnt3a (ng/dl) | 2.7 (1.4-4.3) | 0.5 (0.2-0.9) | < 0.0001 |
| CTNN-β1 (ng/dl) | 3.6 (2.5-4.5) | 0.6 (0.2-1.2) | < 0.0001 |
| ESR (mm/h) | 58 (40-78) | 5.0 (2.2-9.0) | < 0.0001 |
| CRP (mg/l) | 45 (24-76) | 2.0 (1.1-2.9) | < 0.0001 |
| LDH (U/l) | 314 (278-415) | 150 (135-177) | < 0.0001 |
TGF-β1 – transforming growth factor β, SMAD2 – mothers against decapentaplegic homolog 2, Wnt3a – wingless-related integration site, CTNN-β – β-catenin, CRP – C-reactive protein, LDH – lactate dehydrogenase, ESR – erythrocyte sedimentation rate